Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: INFLIXIMAB, . Treffer: 51
2022
Conforti, C; Dianzani, C; Zalaudek, I; Cicala, M; Persichetti, P; Giuffrida, R; Morariu, SH; Neagu, N
Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review.
J Dermatolog Treat. 2020; 1-8.
Doi: 10.1080/09546634.2020.1836313
Web of Science
PubMed
FullText
FullText_MUG
Trevisini, S; Trevisan, G; Zalaudek, I; Bonin, S
Adamantiades-Behçet's disease therapy: current treatment options and recommendations with regard to the COVID-19 pandemic.
Dermatol Ther. 2021; e15286
Doi: 10.1111/dth.15286
Web of Science
PubMed
FullText
FullText_MUG
2021
Blesl, A; Binder, L; Högenauer, C; Wenzl, H; Borenich, A; Pregartner, G; Berghold, A; Mestel, S; Kump, P; Baumann-Durchschein, F; Petritsch, W
Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
Aliment Pharmacol Ther. 2021; 54(5):667-677
Doi: 10.1111/apt.16478
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Hässler, S; Bachelet, D; Duhaze, J; Szely, N; Gleizes, A; Hacein-Bey Abina, S; Aktas, O; Auer, M; Avouac, J; Birchler, M; Bouhnik, Y; Brocq, O; Buck-Martin, D; Cadiot, G; Carbonnel, F; Chowers, Y; Comabella, M; Derfuss, T; De Vries, N; Donnellan, N; Doukani, A; Guger, M; Hartung, HP; Kubala Havrdova, E; Hemmer, B; Huizinga, T; Ingenhoven, K; Hyldgaard-Jensen, PE; Jury, EC; Khalil, M; Kieseier, B; Laurén, A; Lindberg, R; Loercher, A; Maggi, E; Manson, J; Mauri, C; Mohand Oumoussa, B; Montalban, X; Nachury, M; Nytrova, P; Richez, C; Ryner, M; Sellebjerg, F; Sievers, C; Sikkema, D; Soubrier, M; Tourdot, S; Trang, C; Vultaggio, A; Warnke, C; Spindeldreher, S; Dönnes, P; Hickling, TP; Hincelin Mery, A; Allez, M; Deisenhammer, F; Fogdell-Hahn, A; Mariette, X; Pallardy, M; Broët, P; ABIRISK consortium
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
PLoS Med. 2020; 17(10): e1003348-e1003348.
Doi: 10.1371/journal.pmed.1003348
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Bronsky, J; de Ridder, L; Ruemmele, FM; Griffiths, A; Buderus, S; Hradsky, O; Hauer, AC
Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases: Results from a Clinical Practice Survey.
J Pediatr Gastroenterol Nutr. 2019; 68(5):676-683
Doi: 10.1097/MPG.0000000000002233
Web of Science
PubMed
FullText
FullText_MUG
de Ridder, L; Assa, A; Bronsky, J; Romano, C; Russell, RK; Afzal, NA; Hauer, AC; Knafelz, D; Lionetti, P; Strisciuglio, C; Veres, G; Winter, H; Wolters, VM; Sladek, M; Vulto, AG; Dias, JA; Paediatric IBD Porto group of ESPGHAN
Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN.
J Pediatr Gastroenterol Nutr. 2019; 68(1): 144-153.
Doi: 10.1097/MPG.0000000000002141
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2018
Busard, CI; Cohen, AD; Wolf, P; Gkalpakiotis, S; Cazzaniga, S; Stern, RS; Hutten, BA; Feldhamer, I; Quehenberger, F; Lichem, R; Kojanova, M; Adenubiova, E; Addis, A; Naldi, L; Spuls, PI
Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
J Eur Acad Dermatol Venereol. 2018; 32(2):245-253
Doi: 10.1111/jdv.14583
Web of Science
PubMed
FullText
FullText_MUG
Miehsler, W; Dejaco, C; Gröchenig, HP; Fuchssteiner, H; Högenauer, C; Kazemi-Shirazi, L; Maier, H; Mayer, A; Moschen, A; Reinisch, W; Petritsch, W; Platzer, R; Steiner, P; Tilg, H; Vogelsang, H; Wenzl, H; Novacek, G
[Second Austrian consensus on the safe use of anti-TNFα-antibodies in patients with inflammatory bowel diseases].
Z Gastroenterol. 2018; 56(3):275-302
Doi: 10.1055/s-0044-100044
Web of Science
PubMed
FullText
FullText_MUG
Stamm, TA; Machold, KP; Aletaha, D; Alasti, F; Lipsky, P; Pisetsky, D; Landewe, R; van der Heijde, D; Sepriano, A; Aringer, M; Boumpas, D; Burmester, G; Cutolo, M; Ebner, W; Graninger, W; Huizinga, T; Schett, G; Schulze-Koops, H; Tak, PP; Martin-Mola, E; Breedveld, F; Smolen, J
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.
Arthritis Res Ther. 2018; 20(1):174-174
Doi: 10.1186/s13075-018-1667-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Inzinger, M; Wippel-Slupetzky, K; Weger, W; Richter, L; Mlynek, A; Fleischander, B; Scheurecker, C; Sandor, N; Mairhofer, D; Sator, PG; Moser-Oberthaler, S; Häring, N; Viznerova, P; Painsi, C; Tanew, A; Ponholzer, P; Tatarski, R; Brenner, W; Stingl, G; Salmhofer, W; Rappersberger, K; Klein, G; Saxinger, W; Auböck, J; Kölli, C; Trautinger, F; Steiner, A; Ratzinger, G; Strohal, R; Riedl, E; Lange-Asschenfeldt, B; Pehamberger, H; Volc-Platzer, B; Selhofer, S; Legat, FJ; Müllegger, R; Reider, N; Schmuth, M; Hintner, H; Hofer, A; Gruber-Wackernagel, A; Aberer, W; Quehenberger, F; Wolf, P
Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
Acta Derm Venereol. 2016; 96(2):207-212
Doi: 10.2340/00015555-2214
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Narula, N; Kainz, S; Petritsch, W; Haas, T; Feichtenschlager, T; Novacek, G; Eser, A; Vogelsang, H; Reinisch, W; Papay, P
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Aliment Pharmacol Ther. 2016; 44(2):170-80
Doi: 10.1111/apt.13671
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2015
de Ridder, L; Waterman, M; Turner, D; Bronsky, J; Hauer, AC; Dias, JA; Strisciuglio, C; Ruemmele, FM; Levine, A; Lionetti, P; ESPGHAN Paediatric IBD Porto Group
Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.
J Pediatr Gastroenterol Nutr. 2015; 61(4):503-508
Doi: 10.1097/MPG.0000000000000903
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Skrabl-Baumgartner, A; Weger, W; Salmhofer, W; Jahnel, J
Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment.
Pediatr Dermatol. 2015; 32(1):e13-e14
Doi: 10.1111/pde.12457
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
2014
Brunasso, AM; Aberer, W; Massone, C
Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis.
Lupus. 2014; 23(2):201-203
Doi: 10.1177/0961203313517153
Web of Science
PubMed
FullText
FullText_MUG
2013
Papay, P; Miehsler, W; Tilg, H; Petritsch, W; Reinisch, W; Mayer, A; Haas, T; Kaser, A; Feichtenschlager, T; Fuchssteiner, H; Knoflach, P; Vogelsang, H; Platzer, R; Tillinger, W; Jaritz, B; Schmid, A; Blaha, B; Dejaco, C; Sobala, A; Weltermann, A; Eichinger, S; Novacek, G
Clinical presentation of venous thromboembolism in inflammatory bowel disease.
J Crohns Colitis. 2013; 7(9):723-729
Doi: 10.1016/j.crohns.2012.10.008
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2012
Wright, G; Vairappan, B; Stadlbauer, V; Mookerjee, RP; Davies, NA; Jalan, R
Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats.
Liver Int. 2012; 32(3):410-419
Doi: 10.1111/j.1478-3231.2011.02698.x
Web of Science
PubMed
FullText
FullText_MUG
2011
Brunasso, AM; Puntoni, M; Gulia, A; Massone, C
Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.
Rheumatology (Oxford). 2011; 50(9):1700-1711
Doi: 10.1093/rheumatology/ker190
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Brunasso, AM; Puntoni, M; Salvini, C; Delfino, C; Curcic, P; Gulia, A; Massone, C
Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
Acta Derm Venereol. 2011; 91(1):44-49
Doi: 10.2340/00015555-0959
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Inzinger, M; Heschl, B; Weger, W; Hofer, A; Legat, FJ; Gruber-Wackernagel, A; Tilz, H; Salmhofer, W; Quehenberger, F; Wolf, P
Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Br J Dermatol. 2011; 165(3):640-645
Doi: 10.1111/j.1365-2133.2011.10396.x
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Reinisch, W; Dejaco, C; Feichtenschlager, T; Haas, T; Kaser, A; Miehsler, W; Novacek, G; Petritsch, W; Platzer, R; Tilg, H; Vogelsang, H; Knoflach, P; Arbeitsgruppe Chronisch-entzündliche Darmerkrankungen der ÖGGH
Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
Z Gastroenterol. 2011; 49(4):534-542
Doi: 10.1055/s-0029-1245930
Web of Science
PubMed
FullText
FullText_MUG
2010
Dejaco, C; Duftner, C; Klotz, W; Schirmer, M; Herold, M
Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
Rheumatol Int. 2010; 30(4):451-454
Doi: 10.1007/s00296-009-0978-4
Web of Science
PubMed
FullText
FullText_MUG
Miehsler, W; Novacek, G; Wenzl, H; Vogelsang, H; Knoflach, P; Kaser, A; Dejaco, C; Petritsch, W; Kapitan, M; Maier, H; Graninger, W; Tilg, H; Reinisch, W; Austrian Society of Gastroenterology and Hepatology
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
J Crohns Colitis. 2010; 4(3):221-256
Doi: 10.1016/j.crohns.2009.12.001
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Wascher, TC; Lindeman, JH; Sourij, H; Kooistra, T; Pacini, G; Roden, M
Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome.
Mol Med. 2010; 17(3-4):189-193
Doi: 10.2119/molmed.2010.00221
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Weger, W
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents
Br J Pharmacol. 2010; 160(4):810-820
Doi: 10.1111/j.1476-5381.2010.00702.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2009
Aringer, M; Houssiau, F; Gordon, C; Graninger, WB; Voll, RE; Rath, E; Steiner, G; Smolen, JS
Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Rheumatology (Oxford). 2009; 48(11):1451-1454
Doi: 10.1093/rheumatology/kep270
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Brunasso, AM; Delfino, C; Massone, C
Efalizumab rebound response to a sequential therapy of infliximab followed by efalizumab.
Dermatology. 2009; 218(1):73-74
Doi: 10.1159/000163085
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Brunasso, AM; Massone, C
Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis.
J Am Acad Dermatol. 2009; 60(5):781-785
Doi: 10.1016/j.jaad.2008.12.001
Web of Science
PubMed
FullText
FullText_MUG
Dejaco, C; Duftner, C; Wipfler, E; Schirmer, M
A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation
Wien Med Wochenschr. 2009; 159(3-4): 70-75.
Doi: 10.1007/s10354-008-0590-3
PubMed
FullText
FullText_MUG
Fruehauf, J; Cierny-Modrè, B; Caelen, Lel-S; Schwarz, T; Weinke, R; Aberer, E
Response to infliximab in SAPHO syndrome.
BMJ Case Rep. 2009; 2009(10):
Doi: 10.1136/bcr.10.2008.1145
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
2008
Brezinschek, HP; Hofstaetter, T; Leeb, BF; Haindl, P; Graninger, WB
Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate.
Curr Opin Rheumatol. 2008; 20(3):295-299
Doi: 10.1097/BOR.0b013e3282ffdeca
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Brunasso, AM; Delfino, C; Massone, C
Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative?
Br J Dermatol. 2008; 159(3):761-763
Doi: 10.1111/j.1365-2133.2008.08735.x
Web of Science
PubMed
FullText
FullText_MUG
Duftner, C; Dejaco, C; Larcher, H; Schirmer, M; Herold, M
Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic.
Rheumatol Int. 2008; 29(1): 69-73.
Doi: 10.1007/s00296-008-0621-9
Web of Science
PubMed
FullText
FullText_MUG
Lackner, H; Urban, C; Sovinz, P; Benesch, M; Moser, A; Schwinger, W
Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children.
Haematologica. 2008; 93(2): 291-294.
Doi: 10.3324/haematol.11704
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Pföhler, C; Ugurel, S
Cutaneous reactions to molecular targeted therapies.
Hautarzt. 2008; 59(10):814-820
Doi: 10.1007/s00105-008-1540-0
Web of Science
PubMed
FullText
FullText_MUG
2007
Aringer, M; Steiner, G; Graninger, WB; Höfler, E; Steiner, CW; Smolen, JS
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Arthritis Rheum. 2007; 56(1): 274-279.
Doi: 10.1002/art.22327
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Tilg, H; Feichtenschlager, T; Knoflach, P; Petritsch, W; Schöfl, R; Vogelsang, H; Reinisch, W
Use of infliximab in ulcerative colitis.
Z Gastroenterol. 2007; 45(8): 907-911.
Doi: 10.1055/s-2007-963393
Web of Science
PubMed
FullText
FullText_MUG
Wegscheider, BJ; El-Shabrawi, L; Weger, M; Ardjomand, N; Hermann, J; Aberer, E; El-Shabrawi, Y
Adverse skin reactions to infliximab in the treatment of intraocular inflammation.
Eye. 2007; 21(4): 547-549.
Doi: 10.1038/sj.eye.6702262
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2006
Brezinschek, HP; Brickmann, K; Yazdani-Biuki, B; Dörner, T; Graninger, WB; Brezinschek, RI
Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes.
Wien Med Wochenschr. 2006; 156(1-2): 61-67.
Doi: 10.1007/s10354-005-0241-x
PubMed
FullText
FullText_MUG
Google Scholar
de Boer, NK; Reinisch, W; Teml, A; van Bodegraven, AA; Schwab, M; Lukas, M; Ochsenkühn, T; Petritsch, W; Knoflach, P; Almer, S; van der Merwe, SW; Herrlinger, KR; Seiderer, J; Vogelsang, H; Mulder, CJ; Dutch 6-TG working group
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
DIGESTION. 2006; 73(1): 25-31.
Doi: 10.1159/000091662
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Duftner, C; Dejaco, C; Kullich, W; Klauser, A; Goldberger, C; Falkenbach, A; Schirmer, M
Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.
Ann Rheum Dis. 2006; 65(5): 647-653.
Doi: 10.1136/ard.2005.042085
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2005
Deutschmann, A; Mache, CJ; Bodo, K; Zebedin, D; Ring, E
Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage.
PEDIATRICS. 2005; 116(5): 1231-1233.
Doi: 10.1542/peds.2004-2206
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Kneitz, C; Suerbaum, S; Beer, M; Muller, J; Jahns, R; Tony, HP
Exacerbation of Whipple's disease associated with infliximab treatment
Scand J Rheumatol. 2005; 34(2):148-151
Doi: 10.1080/03009740510015230
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2004
Aringer, M; Graninger, WB; Steiner, G; Smolen, JS
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Arthritis Rheum. 2004; 50(10):3161-3169
Doi: 10.1002/art.20576
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Wenzl, HH; Reinisch, W; Jahnel, J; Stockenhuber, F; Tilg, H; Kirchgatterer, A; Petritsch, W
Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up.
EUR J GASTROENTEROL HEPATOL. 2004; 16(8): 767-773.
Doi: 10.1097/01.meg.0000108355.41221.77
Web of Science
PubMed
FullText
FullText_MUG
2003
Hermann, J; Mueller, T; Fahrleitner, A; Dimai, HP
Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factor alpha antibody infliximab.
CLIN EXP RHEUMATOL 2003 21: 473-476.
Web of Science
PubMed
Mangge, H; Heinzl, B; Grubbauer, HM; El-Shabrawi, Y; Schauenstein, K
Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis.
Rheumatol Int. 2003; 23(5):258-261
Doi: 10.1007/s00296-003-0308-1
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Tilg, H; Jalan, R; Kaser, A; Davies, NA; Offner, FA; Hodges, SJ; Ludwiczek, O; Shawcross, D; Zoller, H; Alisa, A; Mookerjee, RP; Graziadei, I; Datz, C; Trauner, M; Schuppan, D; Obrist, P; Vogel, W; Williams, R
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.
J Hepatol. 2003; 38(4):419-425
Doi: 10.1016/S0168-8278(02)00442-7
Web of Science
PubMed
FullText
FullText_MUG
2002
Aringer, M; Graninger, WB
Treating rheumatoid arthritis with new disease modifying drugs.
Acta Med Austriaca. 2002; 29(1):33-35
Doi: 10.1046/j.1563-2571.2002.01042.x
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
El-Shabrawi, Y; Hermann, J
Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis.
Ophthalmology. 2002; 109(12):2342-2346
Doi: 10.1016%2FS0161-6420%2802%2901292-7
Web of Science
PubMed
FullText
FullText_MUG
Graninger, W; Smolen, J
Treatment of rheumatoid arthritis by TNF-blocking agents.
Int Arch Allergy Immunol. 2002; 127(1):10-14
Doi: 10.1159/000048164
Web of Science
PubMed
FullText
FullText_MUG
Weitere 50 Treffer anzeigen